{"disease":{"id":"seizures-associated-with-cdkl5-deficiency-disorders","name":"Seizures associated with CDKL5 deficiency disorders","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ganaxolone","indication_name":"Seizures associated with CDKL5 deficiency disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ztalmy","generic_name":"GANAXOLONE","company_name":"Marinus","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-2/beta-1/gamma-2","drug_class":"Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]","quality_score":48,"revenue":null,"mechanism":"Ztalmy works by enhancing the activity of the GABA A receptor, a key player in regulating the activity of neurons in the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}